News

Esperto is honored to be named Octane's Best Emerging Disruptor of 2024. Octane’s High Tech Awards celebrate the top innovators, entrepreneurs, and technology leaders in Orange County. Over 350 life sciences companies are based here, making the OC one of the country’s top hotspots in medical innovation. Learn more and view the other winners here.

Esperto is proud to be one of twelve startups selected for the inaugural Space Health Accelerator (Space-H). A Microsoft-backed collaboration between NASA’s Human Research Program (NASA HRP), the Translational Research Institute for Space Health (TRISH), and Starburst Aerospace, Space-H aims to drive innovation and investment in next-generation biological and medical technology to enable space exploration. Space-H companies receive guidance from space health subject matter experts and exposure to external funders and investors, with the goal of facilitating the uptake of new space-capable commercial capabilities into NASA HRP. Esperto’s technology offers particular advantages for cardiovascular monitoring during spaceflight, as a continuous, noninvasive solution that never requires calibration.

Esperto’s first publication detailing its novel technique for continuous, noninvasive, calibration-free blood pressure measurement is now available on PNAS Nexus. Lead author Raymond Jimenez and colleagues describe the company’s patented ‘Resonance Sonomanometry’ technique and present the results of its initial clinical validation in humans. (more...).

Esperto has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Utilizing an innovative hub-and-spoke model, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions with the ultimate aim of delivering scalable healthcare outcomes for all Americans. Esperto joins a dynamic nationwide network of organizations aligned to ARPA-H’s overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. As an Investor Catalyst Hub spoke, Esperto gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities and a robust resource library.

Esperto is thrilled to be named among the ten finalists for the UCSF-Stanford Pediatric Device Accelerator competition. Esperto was selected from over 60 applicants for the chance to win up to $100,000 to advance its wearable pediatric vital sign monitor towards clinical testing and marketing clearance. Esperto’s technology measures blood pressure directly and noninvasively using acoustics, offering the possibility to obtain accurate, continuous vital sign data without needles or uncomfortable squeezing cuffs. Winners will be selected at the 5th annual Michael R. Harrison Innovation Symposium on March 22, 2024 in San Francisco.

Bringing new medical technologies to the marketplace is a long expensive process that requires a variety of skills and resources. It can be even more challenging for women and other underrepresented entrepreneurs in biotechnology. Alaina Rajagopal, M.D., Ph.D., spent decades training to be a scientist and physician, but when she co-founded a start-up to bring a non-invasive continuous blood pressure device to customers, she wanted to learn more about entrepreneurship. (more...).

Esperto has secured an investment from the Bill and Melinda Gates Foundation to advance its novel ultrasound-based continuous noninvasive blood pressure measurement device to improve monitoring of pregnant women in low-to-middle income countries (LMICs). Pregnant women are notoriously underdiagnosed and undertreated by the medical community. This is especially true in LMICs, where lack of medical resources and remote location can make monitoring during pregnancy difficult or impossible. For women who reside in traditionally underserved areas, Esperto’s technology could prove lifesaving by longitudinally collecting vital sign data and automatically uploading it to the cloud, enabling a clinician to access the information without the woman ever having to come to the office.

Esperto is proud to be one of ten finalists in the Alliance for Pediatric Device Innovation (APDI) and the Consortium For Technology & Innovation in Pediatrics (CTIP)’s 2023 Make Your Medical Device Pitch for Kids! ™ competition. Children experience serious complications from arterial catheterization at 10 times the rate of adults. By removing the need for invasive blood pressure monitoring, Esperto promises to make intensive care monitoring safer and more comfortable for kids. Esperto will pitch its solution at Children’s National Hospital’s 11th Annual Symposium on Pediatric Device Innovation at the Anaheim Convention Center on Sunday, October 8, 2023 for the chance to win up to $50,000.